S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
NASDAQ:NLSP

NLS Pharmaceutics - NLSP Stock Forecast, Price & News

$1.50
-0.01 (-0.66%)
(As of 03/17/2023 08:54 PM ET)
Add
Compare
Today's Range
$1.45
$1.59
50-Day Range
$1.30
$1.82
52-Week Range
$0.33
$1.88
Volume
51,900 shs
Average Volume
85,379 shs
Market Capitalization
$17.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

NLS Pharmaceutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
233.3% Upside
$5.00 Price Target
Short Interest
Healthy
0.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars


NLSP stock logo

About NLS Pharmaceutics (NASDAQ:NLSP) Stock

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

Receive NLSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.

NLSP Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Maxim Group Keeps Their Buy Rating on NLS Pharmaceutics (NLSP)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
See More Headlines
Receive NLSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.

NLSP Company Calendar

Today
3/20/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NLSP
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+233.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.05 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-0.83

Key Executives

  • Mr. Alexander Zwyer M.B.A. (Age 54)
    Pres, CEO & Director
  • Mr. Chad C. Hellmann M.B.A.
    Chief Financial Officer
  • Mr. Eric Konofal M.D. (Age 56)
    Ph.D., Chief Scientific Officer
  • Dr. Christian C. Wenger Dr. iur. (Age 59)
    L.L.M., LL.M., Ph.D., Gen. Counsel
  • Ms. Sharon Keys
    Head of Regulatory Affairs
  • Dr. George Apostol M.D. (Age 50)
    Chief Medical Officer and Global Head of R&D













NLSP Stock - Frequently Asked Questions

Should I buy or sell NLS Pharmaceutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NLS Pharmaceutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NLSP shares.
View NLSP analyst ratings
or view top-rated stocks.

What is NLS Pharmaceutics' stock price forecast for 2023?

3 brokers have issued 12 month price targets for NLS Pharmaceutics' shares. Their NLSP share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for NLSP
or view top-rated stocks among Wall Street analysts.

How have NLSP shares performed in 2023?

NLS Pharmaceutics' stock was trading at $1.29 at the start of the year. Since then, NLSP shares have increased by 16.3% and is now trading at $1.50.
View the best growth stocks for 2023 here
.

When is NLS Pharmaceutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our NLSP earnings forecast
.

When did NLS Pharmaceutics IPO?

(NLSP) raised $20 million in an initial public offering (IPO) on Friday, January 29th 2021. The company issued 3,600,000 shares at a price of $5.00-$6.00 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager.

What is NLS Pharmaceutics' stock symbol?

NLS Pharmaceutics trades on the NASDAQ under the ticker symbol "NLSP."

How do I buy shares of NLS Pharmaceutics?

Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NLS Pharmaceutics' stock price today?

One share of NLSP stock can currently be purchased for approximately $1.50.

How can I contact NLS Pharmaceutics?

NLS Pharmaceutics' mailing address is ALTER POSTPLATZ 2, STANS V8, CH-6370. The official website for the company is www.nlspharma.com. The company can be reached via phone at 41-44-512-2150 or via fax at 41-41-618-8009.

This page (NASDAQ:NLSP) was last updated on 3/20/2023 by MarketBeat.com Staff